Phase I trials in patients with colon and breast cancer using the anti-LeY solid tumors with immunotoxin LMB-9 are being carried out in collaboration with Dr. Robert Kreitman. LMB-9 is a stable recombinant immunotoxin produced by genetic engineering. Also Dr. Robert Kreitman has completed a Phase I trial on leukemias and lymphomas with immunotoxin LMB-2 [anti-Tac(Fv)-PE38] that targets the alpha subunit of the IL2 receptor. In this trial, 1 complete response and many partial responses were observed. A Phase II trial is being planned. A clinical lot of an immunotoxin (BL22) that targets CD22 present on B-cell malignancies has been produced, and a Phase I trial is ongoing supervised by Dr. Kreitman. This immunotoxin has extremely good activity. Many complete responses have been observed in Hairy Cell Leukemia.
Showing the most recent 10 out of 19 publications